



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

38th Annual Meeting of the Italian Association for the Study of the Liver (A.I.S.F.) (Aula Magna, Università degli Studi di Roma "La Sapienza") Rome, February 16-18, 2005

7th A.I.S.F. PRE-MEETING COURSE

"ADVANCED HEPATOLOGY:

ROLE OF INVASIVE PROCEDURES IN THE DIAGNOSIS AND TREATMENT OF LIVER DISEASES"

Course Directors: S. Faggioli, Padua and F. Marra, Florence

SCIENTIFIC PROGRAMME

Wednesday, February 16

09.30-10.45 Registration and Entry questionnaire

10.45-11.00 Course Presentation
S. FAGIOLI & F. MARRA

Session I

Liver biopsy: time for a change?

Chairpersons: A. ANDRIULLI, *San Giovanni Rotondo*
F. PICCININO, *Naples*

11.00-11.30 What a clinician expects from a liver biopsy
M. BERNARDI, *Bologna*

11.30-12.00 What a pathologist can tell you from a liver biopsy
M. GUIDO, *Padua*

12.00-12.30 Trans-jugular biopsy: a new weapon in the hepatologist's armamentarium
W. DEBERNARDI-VENON, *Turin*

12.30-13.00 **Face To Face:** Biopsy in the management of the transplanted patient
Routinarily. P. BURRA, *Padua*
On demand. L.S. BELLI, *Milan*
Rebuttal. P. BURRA, *Padua*

13.00-14.00 Lunch

Session II

Portal hypertension

Chairpersons: G. D'AMICO, *PALERMO*
C. MERKEL, *PADUA*

14.00-14.30 **Special lecture:**
Evaluation of hepatic hemodynamics: standard of care or research tool?
J. BOSCH, *Barcelona*

14.30-15.00 Endoscopic treatments for portal hypertension
R. DE FRANCHIS, *Milan*

15.00-15.30 TIPS: update 2005
O. RIGGIO, *Rome*

Session III

Diagnosis and treatment of biliary diseases

Chairpersons: M. ANGELICO, *Rome*
M. STRAZZABOSCO, *Bergamo*

15.30-15.55 Radiologic approaches: MRI cholangiography and interventional radiology
G. GANDINI, *Turin*

15.55-16.20 Endoscopic approaches: ERCP and interventional endoscopy
G. COSTAMAGNA, *Rome*

16.20-16.40 Discussion

16.40-17.15 **Break**

Session IV

Focal lesions

Chairpersons: A. ASCIONE, *Naples*
A. CRAXÌ, *Palermo*

17.15-17.35 Image-directed ablative treatments for HCC.
L. BOLONDI, *Bologna*

17.35-17.55 TACE: coming of age?
F. FARINATI, *Padua*

17.55-18.15 Discussion

18.15-18.45 Percutaneous treatment of non-HCC lesions.
G.L. RAPACCINI, *Rome*

18.45-18.50 **Exit questionnaire**

18.50-19.00 **General Assembly I**



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

38th A.I.S.F. Annual Meeting

Rome, February 17-18, 2005

SCIENTIFIC PROGRAMME

Thursday, February 17

- 08.30-10.00 **Oral Communications**
Chairpersons: M. BRUNETTO, Pisa
M. PODDA, Milan
- 08.30-08.45 Low vs standard albumin dosages in the prevention of paracentesis induced circulatory dysfunction: a randomized pilot study
C. Alessandria, A. Marzano, L. Todros, A. Morgando, G. Mengozzi, W. Debernardi-Venon, S. Martini, M. Rizzetto, Turin
- 08.45-09.00 Diastolic dysfunction in cirrhotic patients predicts survival after TIPS
M. Cazzaniga, G. Pagnozzi, S. Visentin, E. Dionigi, A. Carminati, I. Cirello, F. Salerno, Milan
- 09.00-09.15 Sequential versus "ab initio" combined diuretic treatment of moderate ascites in cirrhotic patients: preliminary results of a randomized controlled multicenter clinical study
E. Mazza, P. Angeli, S. Fasolato, E. Zola, S. Guarda, A. Callegaro, A. Galioto, F. Salinas, S. Faggioli, P. Boccagni, E. Miola, A. Sticca, E. Velo, G. Zanus, P. Burra, U. Cillo, G. Baggio, G. Sturniolo, D. D'Amico, A. Gatta, Padua, Cittadella
- 09.15-09.30 Role of endosonography in assessing the rebleeding risk in patients treated with endoscopic variceal ligation
G. de Stefano, A. Giorgio, G. Ferraioli, G. Liorre, A. Di Sarno, C. Coppola, G. Iodice, Naples
- 09.30-09.45 Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B
V. Barbon, S. Gaia, A. Marzano, A. Oliviero, C. Alessandria, A. Ciancio, M. Lagget, M.L. Abate, A. Smedile, M. Rizzetto, Turin
- 09.45-10.00 Liver related mortality in the HAART era in a cohort of HIV infected patients: incidence, risk factors and impact of highly active antiretroviral therapy (HAART)
M. Puoti, K. Prestini, C. Torti, A. Patroni, F. Donato, U. Gelatti, G. Cologni, S. Costarelli, G. Paraninfo, G. Lapadula, V. Tirelli, E. Quiros Roldan, F. Moretti, S. Casari, G. Carosi, Brescia
- 10.00-10.30 **Break and Posters view**
- 10.30-11.30 **General Assembly II**
- 11.30-13.00 **Oral Communications**
Chairpersons: A. MANGIA, S. Giovanni Rotondo
G. PASTORE, Bari
- 11.30-11.45 Opioid receptors are differentially expressed during the process of hepatic stellate cell activation and modulate their proliferation and the development of liver fibrosis: an in vitro and in vivo study
M. Marzoni, G. Sveglia-Baroni, S. De Minicis, S. Saccomanno, A. Benedetti, Ancona
- 11.45-12.00 Bone marrow is a major source of functional myofibroblasts in a murine model of liver fibrosis, without evidence of cell fusion
F.P. Russo, B. Bigger, A. Florou, P. Vig, E. Amofah, G. Bou-Gharios, J.P. Iredale, M.R. Alison, S.J. Forbes, London, Oxford, Southampton, Padua
- 12.00-12.15 A phase II study to evaluate tolerability profile of granulocyte colony stimulating factor (G-CSF) and mobilization of haematopoietic stem cells (HSCs) in patients with liver cirrhosis
S. Lorenzini, A. Isidori, E. Loggi, A. Gramenzi, L. Catani, S. Talarico, C. Cursaro, M. Biselli, F. Bonifazi, R. M. Lemoli, M. Baccarani, M. Bernardi, P. Andreone, Bologna
- 12.15-12.30 Intrahepatic stem cell characterization in organ donors and patients with chronic liver disease
L. Porretti, R. Gramignoli, R. Lopa, A. Ambrosone, A. Cattaneo, A.M. Mosca, F. Colombo, M. Scalomogna, S. Gatti, G. Rossi, A. Colli, D. Prati, Milan, Lecco
- 12.30-12.45 Calcium-dependent activation of NF- κ B by the adipokine resistin in human hepatic stellate cells
C. Bertolani, I. Petrai, S. Aleffi, P. Failli, B. Mazinghi, P. Romagnani, C. Orlando, S. Gelmini, R. DeFranco, M. Pinzani, M. Parola, F. Marra, Florence, Turin
- 12.45-13.00 HCV core protein influences B-cells proliferation by DNP63
A. Alisi, C. Giannini, A. Spaziani, A.L. Zignego, C. Balsano, L'Aquila, Rome, Florence



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- 13.00-13.30 **Lunch and Posters view**
- 13.30-14.00 **Poster discussion**
Viral Section: E. VILLA, *Modena*
Clinical Section: F. ROSINA, *Turin*
- 14.00-15.15 **Genetics and Liver Diseases: where do we stand and where are we going**
Chairpersons: F. MARRA, *Florence*
A. PIETRANGELO, *Modena*
- 14.00-14.20 **Pharmacogenetics**
C.R. SIRTORI, *Milan*
- 14.20-14.40 **Hereditary liver diseases**
S. CALANDRA-BONAURA, *Modena*
- 14.40-15.00 **Gene therapy**
L. FALQUI, *Milan*
- 15.00-15.15 **Discussion**
- 15.15-16.00 **State-of-the-Art Lecture**
Drug-induced liver injury
N. KAPLOWITZ, *Los Angeles, CA (USA)*
- 16.00-16.30 **2004 A.I.S.F. Fellowships Report**
Chairperson: P. LAMPERTICO, *Milan*
- 16.00-16.15 **Bone marrow derived stem cells repopulate the liver of an animal model of congenital metabolic disorder**
C. FERRARESSO, *Padua*
- 16.15-16.30 **Angiogenic mechanisms in liver cirrhosis: role of VEGF in cancer development and portal hypertension**
M.A. IAVARONE, *Milan*
- 16.30-16.45 **Break and poster view**
- 16.45-17.00 **Report of A.I.S.F. Commission on liver transplantation: "use of liver biopsy for the evaluation of donors"**
P. CARACENI, *Bologna*
- 17.00-18.30 **Oral Communications**
Chairpersons: A. FRANCAVILLA, *Bari*
A. MARZANO, *Turin*
- 17.00-17.15 **Microsomal triglyceride transfer protein modulation may explain hepatic steatosis in HCV infected patients**
S. Mirandola, S. Realdon, J. Iqbal, M. Marcolongo, G. Bortoletto, F. Dal Pero, M. Gerotto, MM. Hussain, A. Alberti, Padua, New York
- 17.15-17.30 **Cost effective prediction of sustained response to IFN α 2b or Peg-IFN α 2b plus Ribavirin computing infected cells dynamics by early ALT and HCV-RNA decline**
P. Colombatto, P. Ciccorossi, F. Oliveri, A.M. Maina, L. Civitano, B. Coco, D. Flichman, R. Sacco, F. Bonino, M.R. Brunetto, Pisa, Milan
- 17.30-17.45 **Wild type HCV-NS5A protein and its naturally occurring mutants modulate HBV replication and gene expression**
T. Pollicino, G. Raffa, L. Costantino, G. Squadrito, G. Raimondo, Messina
- 17.45-18.00 **Prophylaxis of Hepatitis B virus recurrence after liver transplantation in carriers of Lamivudine-resistant mutants**
A. Marzano, P. Lampertico, V. Mazzaferro, S. Gaia, M. Viganò, R. Romito, A. Pulvirenti, A. Franchello, M. Colombo, M. Salizzoni, M. Rizzetto, Turin, Milan
- 18.00-18.15 **Histological assessment of donor liver steatosis: one needle sample is adequate!**
M. Guido, M. Fassan, D. Neri, U. Cillo, U. Bareato, P. Burra, M. Rugghe, Padua
- 18.15-18.30 **Ischemic preconditioning reduces the increase of inducible nitric oxide synthase (iNOS) in liver graft and graft injury after transplantation**
A. Grassi, M. Cescon, M. Susca, G. Farina, M. Ravaoli, F. Bianchini, D. Zauli, G.L. Grazi, A. Pinna, F.B. Bianchi, G. Ballardini, Bologna
- ## Friday, February 18
- 08.30-10.00 **Oral Communications**
Chairpersons: S. FAGIUOLI, *Padua*
M. RIZZETTO, *Turin*
- 08.30-08.45 **Effect of phlebotomy on insulin resistance in patients with NAFLD**
S. Colombo, A.L. Fracanzani, A. Guzzo, A. Orsatti, L. Valenti, E. Fatta, A. Maraschi, C. Bertelli, S. Fargion, Milan
- 08.45-09.00 **Plasma adiponectin in non alcoholic fatty liver disease is related to hepatic insulin resistance and hepatic fat content**
E. Vanni, E. Bugianesi, U. Pagotto, E. Gentilcore, R. Manini, A. Gastaldelli, S. Natale, G. Marchesini, M. Rizzetto, Turin, Bologna, Pisa
- 09.00-09.15 **Incidence and natural history of non-alcoholic and alcoholic fatty liver disease (NAFLD, AFLD)**
S. Bellentani, G. Bedogni, L. Miglioli, F. Masutti, L.S. Crocè, A. Castiglione, C. Goldoni, C. Tiribelli, Modena, Trieste
- 09.15-09.30 **PPAR α ligands ameliorate histologic features of NASH by reducing hepatic insulin resistance**
C. Candelaresi, G. Svegliati-Baroni, S. Saccomanno, G. Ferretti, B. Ottanelli, T. Bacchetti, S. De Minicis, A. Omenetti, A. Benedetti, A. Casini, Ancona, Florence



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- 09.30-09.45 Opioid receptor blockage enhances the growth of the biliary tree in experimental cholestasis: evidence for autocrine/paracrine regulation of cholangiocyte proliferation by endogenous opioids
M. Marziani, G. Alpini, S. Saccomanno, S. De Minicis, S. Glaser, L. Trozzi, H. Francis, J. Venter, G. Macarri, A. Benedetti, Ancona, Temple, Texas
- 09.45-10.00 The intrahepatic biliary epithelium is a target of the growth hormone/IGF1 axis
D. Alvaro, V. Drudi Metalli, P. Onori, A. Franchitto, B. Barbaro, A. Torrici, V. Cardinale, A.F. Attili, E. Gaudio, Rome
- 10.00-10.30 **Break and Poster view**
- 10.30-11.15 **State-of-the-Art Lecture**
Why don't we have a vaccine against hepatitis C virus?
P. FARCI, Cagliari
- 11.15-12.45 **3rd A.I.S.F./SIGEP Mini-Symposium PEDIATRIC DISEASES OF THE BILIARY TREE**
*Chairpersons: D. ALVARO, Rome
G. MAGGIORE, Pisa*
- 11.15-11.30 Biliary atresia
G. MAGGIORE, Pisa
- 11.30-11.45 Progressive familial intrahepatic cholestasis
M. STRAZZABOSCO, Bergamo
- 11.45-12.00 Polycystic liver disease
E. GAUDIO, Rome
- 12.00-12.15 Hepato-biliary disease in cystic fibrosis
C. COLOMBO, Milan
- 12.15-12.45 Discussion
- 12.45-13.30 **Lunch and Poster view**
- 13.30-14.45 **General Assembly III**
- 14.45-15.15 **Poster discussion**
Liver Transplantation: *P. ANGELI, Padua*
Basic Science: *A. GASBARRINI, Rome*
- 15.15-15.30 **Presentation of the A.I.S.F./FADE prize for the best Italian paper in 2003**
Presenter: C. FERRARI, Parma
"Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells"
*CALIGIURI A, DE FRANCO RM, ROMANELLI RG, GENTILINI A, MEUCCI M, FAILLI P, MAZZETTI L, ROMBOUTS K, GEERTS A, VANASIA M, GENTILINI P, MARRA F, PINZANI M.
Gastroenterology 2003 Feb;124(2):504-20.*
- 15.30-15.45 **Presentation of the A.I.S.F. distinguished service award to Prof. Livio Capocaccia**
Presenter: A. BENEDETTI, Ancona
- 15.45-17.15 **Oral Communications**
*Chairpersons: A. ALBERTI, Padua
M. PUOTI, Brescia*
- 15.45-16.00 Serum SCCA-IgM complexes increase over time and HCC development in cirrhotic patients
S. Quarta, C. Caberlotto, L. Beneduce, F. Castaldi, M. Marino, G. Fassina, N. Tono, L. Cavalletto, L. Chemello, A. Gatta, P. Pontisso, Padua, Pozzuoli (NA)
- 16.00-16.15 Prevention of intrahepatic HCC recurrence after surgical resection by 131-iodine-lipiodol
M. Tabone, C. Laudi, L. Viganò, R. Pellerito, P. Carbonatto, A. Pera, L. Capussotti, Turin, Candiolo
- 16.15-16.30 Prevalence of naturally occurring S-gene mutants of hepatitis B virus in HBsAg negative patients with hepatocellular carcinoma and controls
A. Tagger, M.L. Ribero, E. Menatti, F. Azzario, U. Gelatti, L. Covolo, F. Donato, Milan, Brescia
- 16.30-16.45 Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation.
F. Azzaroli, A. Colecchia, F. Lodato, M. Montagnani, M.L. Bacchi Reggiani, D. Festi, V. Feletti, G.M. Prati, E. Accogli, S. Casanova, M. Derenzini, E. Roda, G. Mazzella, Bologna
- 16.45-17.00 Characterization of small nodules in liver cirrhosis by the assessment of the vascular pattern at imaging techniques. the problem of "hypovascular" HCC.
L. Bolondi, S. Gaiani, N. Celli, R. Golfieri, W.F. Grigioni, G. Donati, S. Leoni, A.M. Venturi, F. Piscaglia, Bologna
- 17.00-17.15 IFN impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long term Italian multicenter AISF study
F. Oliveri, M. Puoti, T. Santantonio, P. Lampertico, G. Colloredo, G. Niro, G. Fattovich, F. Morisco, A. Marrone, P. Costa, M. Felder, P. Cacciato, A. Smedile, M.R. Brunetto. IFN and HBeAg negative Chronic Hepatitis B A.I.S.F. Study Group
- 17.15-17.30 **Young Investigators Awards**
*Presenters: M. PINZANI, Florence
T. SANTANTONIO, Bari*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

Poster Session

1 Ursodeoxycholic acid stimulates fluid secretion in mice bile ducts through a CFTR- and PKC α -PKC ϵ -dependent mechanism

R. Fiorotto, C. Spirlì, G. Milan, L. Okolicsanyi, M. Strazzabosco, Padua, Bergamo

2 K-canreotate decreases the cumulative incidence of de novo ascites and worsening of variceal status in compensated cirrhosis. A double-blind randomized study

L. Bolondi, F. Piscaglia, A. Gatta, F. Salerno, M. Bernardi, A. Ascione, O. Ferrà, D. Sacerdoti, S. Visentin, F. Trevisani, G. Donati, R. Mazzanti, U. Arena, P. Gentilini and the DOC ("Decrease Of Complications") Study Group, Bologna, Padua, Milan, Naples, Messina, Florence

3 Cirrhotic patients responders and non-responders to nadolol as a primary prophylaxis: Echo-colour-Doppler characterization

A. Berzigotti, S. Dapporto, D. Palmarini, N. Castaldini, C. Rossi, M.C. Morelli, D. Magalotti, P. Andreone, M. Zoli, Bologna

4 Mortality for Liver Cirrhosis in Italy

M. De Luca, G.G. Di Costanzo, F.P. Picciotto, F. Lampasi, L. Addario, A. Galeota Lanza, M.T. Tartaglione, G. Tritto, A. Ascione, Naples

5 Inherited coagulation disorders in cirrhotic patients with and without portal vein thrombosis (PVT)

A. De Santis, F. Cristofari, F. Gigliotti, S. Trapani, R. Moscatelli, L. Conti, F. Guadagni, A. Magnapera, A.F. Attili, Rome

6 Increased prevalence of PIS alpha1-antitrypsin allele in Italian patients with non alcoholic fatty liver disease

L. Valenti, P. Dongiovanni, A. Guzzo, S. Colombo, P. Loria, A. Piperno, A. Casiraghi, R. Ceriani, A.L. Fracanzani, S. Fargion, Milan

7 A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in non-alcoholic fatty liver disease

E. Vanni, E. Bugianesi, G. Marchesini, E. Gentilecore, R. Marzocchi, M. Rizzetto, Turin, Bologna

8 Leptin, leptin-adiponectin ratio and insulin resistance are related with steatosis but not fibrosis in HCV chronic hepatitis

G. Venezia, O. Lo Iacono, S. Petta, M. Amato, V. Rodolico, A. Mattina, C. Giordano, V. Di Marco, C. Mineo, S. De Lisi, P. Almasio, A. Craxi, Palermo

9 The virologic and histologic status in anti-HCV+ve subjects with normal ALT levels: results of a ten-year prospective follow-up study

C. Vandelli, F. Renzo, M. Vandelli, A. Bagni, M. Ponz de Leon, Modena-Reggio Emilia

10 Regression of low-grade lymphoma after interferon-based treatment of hepatitis C virus infection

C. Mazzaro, G. Pozzato, M. Spina, U. Tirelli, A. Tellan, F. Zorat, L. Virgolini, Pordenone, Aviano, Trieste

11 Highly homogeneous E2-HCV associated with the expansion of specific B cell monoclones in patients with mixed cryoglobulinemia

S. Ferri, M. Gerotto, G. Bortoletto, F. Dal Pero, L. Trentin, F. B. Bianchi, M. Lenzi, A. Alberti, Padua, Bologna

12 Insulin resistance occurs rapidly after liver transplantation in HCV positive, but not in HCV negative subjects: role of impaired hepatic insulin extraction

A. Eramo, M. Siciliano, R. De Marco, M.A. Burza, F. Liguori, M. Merli, M. Rossi, G. Novelli, G. Ferretti, P. Berloco, A.F. Attili, S. Ginanni Corradini, Rome

13 Hepatic expansion of a regulatory specific CD8+ T cell population in chronic HCV infection

M. Paroli, D. Accapezzato, V. Francavilla, M. Casciaro, L. Valeria Chircu, A. Cividini, S. Abrignani, M.U. Mondelli, V. Barnaba, Rome, Pavia, Siena

14 Steatosis in children with chronic hepatitis C virus genotype 1 infection is related to body mass index

M. Guido, F. Bortolotti, P. Jara, L. Zancan, L. Giacomelli, M. Fassan, M. Rugge, Padua

15 Soluble Tumor necrosis factor-related Apoptosis-inducing Ligand (sTRAIL) levels during antiviral treatment for chronic hepatitis C

F. Torre, N. Pelli, A. Delfino, M. Basso, A. Picciotto, Genoa

16 Follow-up of HCV carriers with persistently normal ALT levels

N. Bergami, R. Castellacci, L. Bellis, F. Montagnese, P. Petrone De Luca, C. Puoti, Genzano, Rome

17 Viral kinetics of PEG-IFN α 2a. and α 2b plus ribavirin (RBV) in chronic HCV PTS: an Italian cohort study

A. Mangia, V. Paziienza, A. Lonoce, F. Spirito, V. Attino, R. Santoro, A. Andriulli, San Giovanni Rotondo

18 Occult hepatitis B virus and hepatocellular carcinoma: a case-control study

F. Donato, M.L. Ribero, E. Menatti, U. Gelatti, L. Covolo, G. Nardi, M. Puoti, A. Tagger, Milan, Brescia

19 Occult HBV infection is associated with the development of HCC in chronic hepatitis patients

G. Squadrito, T. Pollicino, I. Cacciola, G. Caccamo, T. Restuccia, T. La Masa, G. Raimondo, Messina

20 Intrahepatic dissemination of hepatocellular carcinoma (HCC) after radiofrequency thermal ablation (RFTA)

M. De Giorgio, A. Balzan, D. Marino, C. Angonese, U. Cillo, A. D'Alessandro, M. De Antoni, A. Masotto, M. Massani, M. Mazzucco, E. Miola, D. Neri, D. Paccagnella, G. Pivetta, L. Tommasi, F. Tremolada, A. Tufano, G. Zanùs, F. Farinati, Padua



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

21 Role of contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients

A. Giorgio, G. Ferraioli, G. de Stefano, C. Coppola, L. Del Viscovo, A. Di Sarno, Naples

22 Radiofrequency ablation of HCC can enhance T cell reactivity to hepatoma and non-tumor related antigens

A. Zerbini, A. Penna, M. Pilli, G. Pelosi, S. Schivazzappa, G. Poggi, F. Fagnoni, C. Ferrari, G. Missale, Parma, Pavia

23 Doxorubicin coupled to lactosaminated albumin. A potential drug for a systemic chemotherapy of hepatocarcinomas maintaining the asialoglycoprotein receptor

L. Fiume, L. Bolondi, G. Di Stefano, R. Righini, A. Lanzi, P. Chieco, Bologna

24 Role of occult infection of hepatitis B virus on virus reactivation occurring in Non-Hodgkin Lymphoma patients treated with chemotherapy

M. Persico, E. Persico, M. Picardi, B. Rotoli, B. Palmentieri, F. Carrino, C. Marzocchella, R. Torella, A. De Renzo, Naples

25 Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long?

F. Signorile, M. Fasano, L. Chidichimo, A. Guastadisegni, G. Pastore, T. Santantonio, Bari

26 Versant 3.0 and Cobas TaqMan for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adeфовir combination therapy

P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M. Iavarone, G. Colucci, M. Colombo, Milan, Rotkreuz, Switzerland

27 Late graft dysfunction & autoantibodies after pediatric liver transplantation

A. Sonzogni, S. Riva, P. Stroppa, M.L. Melzi, M. Candusso, A. Bertani, A. Lucianetti, D. Alberti, M. Spada, B. Gridelli, M. Colledan, G. Torre, Bergamo, Palermo

28 Autofluorescence: a real time parameter of liver metabolism during experimental transplantation

A.C. Croce, R. Bertone, I. Freitas, U. Bareato, D. Neri, A. Ferrigno, M. Vairetti, G. Bottiroli, Pavia, Padua

29 Allelic variants of the angiotensin-converting enzyme and graft steatosis/fibrosis in liver transplantation recipients with hepatitis C

P. Toniutto, R. Minisini, M. Caldato, C. Avellini, C. Fabris, C. Smirne, B. Bertoncelli, E. Rossi, E. Fumo, S. Fumagalli, S. Fangazio, M. Pirisi, Udine, Novara

30 Anti-polymerized actin antibodies by ELISA in type 1 autoimmune hepatitis

A. Granito, L. Muratori, P. Muratori, G. Pappas, M. Guidi, R. Bortolotti, M. Lenzi, F.B. Bianchi, Bologna

31 Effect of the cannabinoid CB₁ receptor antagonist SR 141716 in a rat model of liver inflammation

M. Domenicali, A.M. Pertosa, B. Cavalieri, M.G. Perrelli, A. Principe, J. Cutrin, T. Croci, M. Bernardi, P. Caraceni, Bologna, Turin, Milan

32 Nuclear receptor expression in human liver and regulation of bile acid synthesis

C. Gabbi, M. Bertolotti, C. Anzivino, M. Crestani, N. Mitro, C. Godio, E. De Fabiani, M. Del Puppo, L. Carulli, G. Natalini, P. Loria, N. Carulli, Modena, Reggio Emilia, Milan

33 A novel sodium overload test predicting ascites decompensation in rats with CCl₄-induced cirrhosis

M. Domenicali, P. Caraceni, A. Principe, A.M. Pertosa, G. Farneti, A. Zambruni, F. Trevisani, M. Bernardi, Bologna

34 Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?

S. Petta, O. Lo Iacono, G. Venezia, V. Di Marco, G. Ambrosiano, S. De Lisi, C. Mineo, G. Tarantino, F. Barbaria, P. Almasio, A. Craxi, Palermo

35 Rat hepatocyte-homologous acellular matrix (HAM) sandwich transplanted into Gunn rats

S. Tomat, E. Gringeri, F. Calabrese, P.P. Parnigotto, R. Naccarato, P. Burra, Padua

36 Human stem Cell therapy improves the hepatic regeneration modifying microenvironmental gene expression pattern

A.C. Piscaglia, M.A. Zocco, C. Di Campli, M. Novi, G. Di Gioacchino, S. Rutella, G. Bonanno, G. Monego, R. Flore, S. Mancuso, P. Pola, G. Leone, F. Michetti, G. Gasbarrini, A. Gasbarrini, Rome